• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problems Use of Device Problem (1670); Patient-Device Incompatibility (2682); Device Markings/Labelling Problem (2911)
Patient Problem Paralysis (1997)
Event Type  Injury  
Event Description
Paralyzed [paralysis].Off label use of device [wrong location] [off label use of device].Case (b)(6) is a serious spontaneous case received from a consumer in united states.This report concerns a male of unknown age who became paralyzed, after receiving injections in his spine of euflexxa (sodium hyaluronate) solution for injection unknown route of administration, concentration, and dosing regimen, for an unknown indication from an unknown start date to an unknown stop date.The reporter stated that her son's male co-worker received euflexxa injections in his spine, he was paralyzed and "it almost killed him".The event paralyzed was assessed as serious (medically significant).Action taken with euflexxa was unknown.On an unknown date, the outcome of paralyzed was unknown.Concomitant medication and medical history were not reported.At the time of reporting the case outcome was unknown.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: unassessable.Other case numbers: case number, others = (b)(6).This ae occurred in the us and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in (b)(6) because it did not occur in a (b)(6) country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1% SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS  83104
Manufacturer (Section G)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS   83104
Manufacturer Contact
100 interpace parkway
parsippany, NJ 07054
9737961600
MDR Report Key7345508
MDR Text Key102627893
Report Number3000164186-2018-00009
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P010029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Reporter Occupation Other
Type of Report Initial
Report Date 03/16/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/16/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Date Manufacturer Received02/26/2018
Is the Device Single Use? Yes
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Other;
-
-